Recursion Pharmaceuticals Stock Hits Day Low of $3.33 Amid Price Pressure

Recursion Pharmaceuticals, Inc. has experienced significant volatility today, with the stock hitting an intraday low of USD 3.33, reflecting a decline of -8.33% as of February 23, 2026. This performance is part of a broader trend, as the company has seen a -0.29% change over the past day, contrasting with the S&P 500's gain of 0.69%. Over the past week, Recursion Pharmaceuticals has declined by -2.29%, and its one-month performance shows a notable drop of -27.91%. Year-to-date, the stock is down -16.63%, and its one-year performance reveals a staggering -63.25% decline, significantly underperforming the S&P 500, which has risen by 12.95% during the same period. The company's financial metrics indicate challenges, with a net profit of USD -374.38 million and a concerning operating cash flow of USD -383.03 million. Additionally, the stock's long-term performance has been below par, with a -89.5% decline over the past five and ten years. As a small-cap player in the pharmaceuticals and biotechnology sector, Recursion Pharmaceuticals continues to face a challenging market environment.